BiomX:预计不再进行额外的非临床研究,FDA对CMC的意见与现有的制造与质量战略一致
BiomX:预计不再进行额外的非临床研究,FDA对CMC的意见与现有的制造与质量战略一致
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.